Q-omics provides the consensus-scored TMEM196 profile across patient tissues and cancer cell-line models. TMEM196 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, TMEM196 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, TMEM196 RNA expression shows 10,672 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight THCA, COAD, and TGCT as cancer lineages where TMEM196 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM196 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM196 survival associations across molecular data types. TMEM196 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM196 RNA expression–survival associations across cancer types. High TMEM196 expression shows unfavorable associations in THCA, UVM, LIHC, OV and UCEC, but favorable associations in LGG. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for TMEM196 RNA expression.
This table summarizes TMEM196 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM196. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM196 shows lower tumor expression in COAD, UCEC, THCA and KICH and higher tumor expression in KIRC and KIRP. The COAD box plot shows higher TMEM196 RNA expression in normal versus tumor tissue (log2 FC = −0.113, t-test p < 0.001).
This table shows molecular features associated with TMEM196 in patient tissues and cancer cell lines. In patient samples, TMEM196 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM196 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LUNG_SCLC.
